Evidence map›Paper›PMID 39271561›Full record

ArticleProbiotics and antimicrobial proteins2025

Functional Effects of Probiotic Lactiplantibacillus plantarum in Alleviation Multidrug-Resistant Escherichia coli-Associated Colitis in BALB/c Mice Model.

Mohamedelfatieh Ismael, Nageena Qayyum, Yaxin Gu, Li Na, Han Haoyue, Muhammad Farooq, Panpan Wang, Qingping Zhong, Xin Lü

Abstract read
PubMed Publisher
In one paragraph

Article in Probiotics and antimicrobial proteins, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Foods (Basel, Switzerland) · 2026
    Article
  2. Impact of Dietary Interventions withFoods (Basel, Switzerland) · 2026
    Article
  3. Review
  4. Antimicrobial Activity ofAntibiotics (Basel, Switzerland) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mohamedelfatieh IsmaelGuangdong Provincial Key Laboratory of Food Quality and Safety, College of Food Science, South China Agricultural University, Guangzhou, 510642, China.
Nageena QayyumLab of Bioresource, College of Food Science and Engineering, Northwest A&F University, Yangling, 712100, China.
Yaxin GuCollege of Food Science, China Agricultural University, Beijing, China.
Li NaLab of Bioresource, College of Food Science and Engineering, Northwest A&F University, Yangling, 712100, China.
Han HaoyueLab of Bioresource, College of Food Science and Engineering, Northwest A&F University, Yangling, 712100, China.
Muhammad FarooqLab of Bioresource, College of Food Science and Engineering, Northwest A&F University, Yangling, 712100, China.
Panpan WangLab of Bioresource, College of Food Science and Engineering, Northwest A&F University, Yangling, 712100, China.
Qingping ZhongGuangdong Provincial Key Laboratory of Food Quality and Safety, College of Food Science, South China Agricultural University, Guangzhou, 510642, China. zhongqp@scau.edu.cn.
Xin LüLab of Bioresource, College of Food Science and Engineering, Northwest A&F University, Yangling, 712100, China. xinlu@nwsuaf.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multidrug-resistant Escherichia coli (MDR-E. coli) is a global health concern. Lactic acid bacteria (LAB) are important probiotics that have beneficial effects on health, and in recent years, their influences in preventing foodborne pathogens-induced colitis have attracted much attention. Therefore, this study aimed to investigate the oral administration of Lactiplantibacillus plantarum NWAFU-BIO-BS29 as an emerging approach to alleviate MDR-E. coli-induced colitis in BALB/c mice model. To illustrate the mode of action of NWAFU-BIO-BS29 interventions with the gut microbiota and immune responses, the changes on the colonic mucosal barrier, regulatory of the gene expressions of inflammatory cytokines, re-modulating the intestinal microflora, and changes in physiological parameters were studied. The results indicated that daily supplementation of 200 µL fresh bacteria for 7 days had ameliorated the associated colitis and partially prevented the infection. The modes of action by ameliorating the inflammatory response, which destructed villous and then affected the intestinal barrier integrity, reducing the secretion of interleukins (6 and β) and tumor necrosis factor (TNF-α) in serum by 87.88-89.93%, 30.73-35.98%, and 19.14-22.32%, respectively, enhancing the expressions of some epithelial integrity-related proteins in the mouse mucous layer of mucins 2 and 3, Claudin-1, and Occludin by 130.00-661.85%, 27.64-57.35%, 75.52-162.51%, and 139.36-177.73%, respectively, and 56.09-73.58% for toll-like receptor (TLR4) in colon tissues. Notably, the mouse gut microbiota analysis showed an increase in the relative abundance of beneficial bacteria, including Lactobacillus, Bacteriodales bacterium, Candidatus Saccharimonas, Enterorhabdus, and Bacilli. Furthermore, the probiotic promoted the proliferation of epithelia and goblet cells by increasing short-chain fatty acids (SCFAs) levels by 19.23-31.39%. In conclusion, L. plantarum NWAFU-BIO-BS29 has potential applications and can be considered a safe dietary supplement to ameliorate the colitis inflammation symptoms of MDR-E. coli infection.

Indexed as

ColitisEscherichia coliEscherichia coli InfectionsLactiplantibacillus plantarumProbioticsAnimalsColonCytokinesDisease Models, AnimalDrug Resistance, Multiple, BacterialGastrointestinal MicrobiomeIntestinal MucosaMaleMiceMice, Inbred BALB CCytokinesGut microbiotaImmune systemInflammatory cytokine expressionLactiplantibacillus plantarumMultidrug-resistant Escherichia coliProbiotics

Identifiers

PMID39271561

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.